Biographical Sketch



1. Name

Yeul Hong Kim

2. Education

Institution and Location	Inclusive Dates of Attendance	Degree and Date	Major
College of Medicine, Korea University,	Mar. 1977-Feb. 1983	M.D., Feb. 1983	Medicine
Seoul. Korea.			
Graduate School of Korea University,	Mar. 1985-Feb. 1987	M.S., Feb. 1987	Internal
Seoul. Korea.			Medicine
Graduate School of Korea University,	Mar. 1987-Feb. 1993	Ph.D., Feb. 1994	Internal
Seoul. Korea.			Medicine

3. Professional experience in reverse order, starting with present

Title of Position	Name and Address of Employer	Inclusive Dates
Director	Korea Precision Medicine Enterprise	2017-2022
Director	Korea University Anam Hospital Clinical Trial Center2014-2016	
Director	Korea University Anam Hospital Cancer Center	2005-2016
Professor	Korea University Medical College, Seoul. Korea	2002 - present
Director	Lung, Breast/Ovarian Cancer Genomic Research	2001-2011
	Center	
Visiting Scientist	M.D. Anderson Cancer Center, Houston. Texas	9/2001-11/2001
Associate Professor	Korea University Medical College, Seoul. Korea	1997-2002
Assistant Professor	Korea University Medical College, Seoul. Korea	1995-1997
Postdoctoral Fellow	M.D. Anderson Cancer Center, Houston. Texas	1994-1995
Deputy Chairman,	Seoul Adventist Hospital, Seoul. Korea	1992-1993
	Dept. of Int. Med.	
Postdoctoral Fellow	M.D. Anderson Cancer Center, Houston. Texas	1991-1992

Clinical Fellow	Korea University Hospital, Seoul. Korea	1990-1991		
4. Academic Society activities				
Chairman of Board	Korea Cancer Association	2016-2018		
Chairman of Organizing Committee, 24th APCC		2017		
President	Asian Clinical Oncology Society	2016-present		
President	Korea Genome Organization	2013-2013		
Chairman of Scientific Committee, Korea Cancer Association		2012-2016		
Chairman of Organizing Committee, 10th ACOS		2012		
President	Korean Cancer Study Group	2010-2012		
Secretary General	Korea Cancer Association	2008-2010		
Chairman of Gastric cancer subcommittee, Korean Cancer Study Group		2007-2010		
Secretary General	Korea Association of Clinical Oncology	2005-2008		
Deputy Chairman of Publishing Committee, Korea Cancer Association		2004-2008		
Secretary General	Korean Cancer Study Group	2003-2005		
Member of Academic Committee, Korea Cancer Association		2002-2008		
Member of Publishing Committee, Korea Cancer Association		2000-2008		

5. Representative Publications

- 1. Kim HS, Sung JS, Kim YH, et al. (2013) Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma. **PLoS One.** 8(12):e81975.
- 2. Jo U, Park KH, Kim YH, et al. (2014) EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR. **Oncotarget.** 15;5(5):1265-78.
- 3. Machiela MJ, Zhou W, Sampson JN, Kim YH, et al. (2015) Characterization of large structural genetic mosaicism in human autosomes. **Am J Hum Genet.** 96(3):487-97.
- 4. Bang YJ, Im SA, Lee KW, Cho JY, Song EK, Lee KH, Kim YH, et al. (2015) Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. J Clin Oncol. 33(33):3858-65.
- Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, Lan Q, Kim YH, et al. (2015) Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. J Natl Cancer Inst. 107(12):djv279.
- 6. Machiela MJ, Zhou W, Karlins E, Sampson JN, Freedman ND, Yang Q, Kim YH, et al. (2016) Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. **Nat** Commun. 7:11843
- 7. Seow WJ, Matsuo K, Hsiung CA, Shiraishi K, Song M, Kim HN, Wong MP, Hong YC, Hosgood HD 3rd, Wang Z, Chang IS, Wang JC, Chatterjee N, Tucker M, Wei H, Mitsudomi T, Zheng W, Kim JH, Zhou B, Caporaso NE, Albanes D, Shin MH, Chung LP, An SJ, Wang P, Zheng H, Yatabe Y, Zhang XC, Kim YT, Shu XO, Kim YC, Bassig BA, Chang J, Ho JC, Ji BT, Kubo M, Daigo Y, Ito H, Momozawa Y, Ashikawa K, Kamatani Y, Honda T, Sakamoto H, Kunitoh H, Tsuta K, Watanabe SI, Nokihara H, Miyagi Y, Nakayama H, Matsumoto S, Tsuboi M, Goto K, Yin Z, Shi J, Takahashi A, Goto A, Minamiya Y, Shimizu

K, Tanaka K, Wu T, Wei F, Wong JY, Matsuda F, Su J, Kim YH, et al. (2017) Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. **Hum Mol Genet.** 2017 Jan 15;26(2):454-465.

- Bang YJ, Cho JY, Kim YH, Kim JW, Di Bartolomeo M, Ajani JA, Yamaguchi K, Balogh A, Sanchez T, Moehler M. (2017) Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clin Cancer Res. 23(19):5671-5678.
- Hyun MH, Sung JS, Kang EJ, Choi YJ, Park KH, Shin SW, Lee SY, Kim YH. (2017) Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer. Oncotarget. 10;8(55):94417-94430.
- 10. Sung JS, Chong HY, Kwon NJ, Kim HM, Lee JW, Kim B, Lee SB, Park CW, Choi JY, Chang WJ, Choi YJ, Lee SY, Kang EJ, Park KH, Kim YH. (2017) Detection of somatic variants and *EGFR* mutations in cell-free DNA from non-small cell lung cancer patients by ultra-deep sequencing using the ion ampliseq cancer hotspot panel and droplet digital polymerase chain reaction. **Oncotarget.** 15;8(63):106901-106912.

Tel: 82-2-920-5569

Fax: 82-2-926-4534

E-mail: <u>yhk0215@korea.ac.kr</u>

Address: Section of Medical Oncology, Department of Internal Medicine, Korea University Anam Hospital, 126-1, Anam-dong 5 Ga, Sungbuk-Gu, Seoul 136-705, Korea

2018-9-29